HEDERA-22 is a spin-off from ULiege specialized in bioinformatics, microbiology, genetic engineering and metabolomics. HEDERA-22 aims to propose to pharmaceutical and agrochemical companies novel process for the discovery of unknown bioactive molecules. Its unique strategy based on predictive bio informatic approaches and on an exclusive data base of gene regulation mechanisms allows to target strains of interest as well as production conditions leading to the expression of cryptic metabolites. This strategy substantially speeds up the discovery of new compounds versus the classical random screening methods with low success factor. HEDERA-22 is building its own next generation biomolecules library with identified activity, which is made available for screening to partners for licensing or partnership. Its objective is to participate in the challenge for better health and a better planet by developing sustainable products for pharma and plant protection.